These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20690034)

  • 1. Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation.
    Chen CH; Chen HA; Liao HT; Liu CH; Tsai CY; Chou CT
    Clin Rheumatol; 2010 Oct; 29(10):1155-61. PubMed ID: 20690034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
    Kim HR; Lee SH; Kim HY
    Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing spondylitis patients carrying different HLA-B27 subtypes.
    Mou YK; Zhang PP; Li QX; Lin ZM; Liao ZT; Wei QJ; Gu JR
    Clin Rheumatol; 2015 Jun; 34(6):1085-9. PubMed ID: 25912212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis.
    Dovio A; Data V; Carignola R; Calzolari G; Vitetta R; Ventura M; Saba L; Severino A; Angeli A
    J Rheumatol; 2008 Nov; 35(11):2206-13. PubMed ID: 18843778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of cigarette smoking with Chinese ankylosing spondylitis patients in Taiwan: a poor disease outcome in systemic inflammation, functional ability, and physical mobility.
    Chen CH; Chen HA; Lu CL; Liao HT; Liu CH; Tsai CY; Chou CT
    Clin Rheumatol; 2013 May; 32(5):659-63. PubMed ID: 23329350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Levels of
    Chen M; Hu X; Wu M; Yang J; Han R; Ma Y; Zhang X; Yuan Y; Liu R; Wang M; Jiang G; Deng J; Xu S; Xu J; Shuai Z; Pan F
    Immunol Invest; 2019 Jul; 48(5):490-504. PubMed ID: 30689477
    [No Abstract]   [Full Text] [Related]  

  • 9. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
    Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
    Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
    Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH; Lee HJ; Sung IH; Kim TH
    J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.
    Carmona-Fernandes D; Santos MJ; Perpétuo IP; Fonseca JE; Canhão H
    Arthritis Res Ther; 2011; 13(5):R175. PubMed ID: 22027240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between insulin resistance, hs-CRP, and body fat and serum osteoprotegerin/RANKL in prediabetic patients.
    Bilgir O; Yavuz M; Bilgir F; Akan OY; Bayindir AG; Calan M; Bozkaya G; Yuksel A
    Minerva Endocrinol; 2018 Mar; 43(1):19-26. PubMed ID: 28146138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
    Taylan A; Sari I; Akinci B; Bilge S; Kozaci D; Akar S; Colak A; Yalcin H; Gunay N; Akkoc N
    BMC Musculoskelet Disord; 2012 Oct; 13():191. PubMed ID: 23025387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
    Kananen K; Volin L; Laitinen K; Ruutu T; Välimäki MJ
    Osteoporos Int; 2006; 17(5):724-30. PubMed ID: 16437190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
    Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
    Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.
    Klingberg E; Nurkkala M; Carlsten H; Forsblad-d'Elia H
    J Rheumatol; 2014 Jul; 41(7):1349-56. PubMed ID: 24931960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
    J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.